Innovative Biopharmaceuticals from Oral Science
Oragenics is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease.
Learn More About OragenicsOragenics Acquires Noachis Terra, Inc.
NIH-created SARS-CoV-2 (COVID-19) Spike Protein Vaccine Technology could provide specific immunity from the novel coronavirus (“SARS-CoV-2”), the root cause of coronavirus disease 2019 (“COVID-19”).
Learn More about the Acquisition of Noachis Terra
Fighting Global Bacterial Antibiotic Resistance
Oragenics, in collaboration with Precigen, is in the process of developing lantibiotics, a novel class of antibiotics that are known to be active against several life-threatening infectious agents, toward the goal of commercialization for the treatment of infectious diseases in humans.
Learn More About Lantibiotics
